The findings in this study suggest that AMPK-activating compounds, some of which have been used for decades to treat metabolic disorders, can be useful for the treatment of cancer, and provide a mechanistic explanation for the cancer-preventing effects of AMPK-activating compounds [71,72,73]. The gene discussed is PRKAA2; the disease is Other metabolic disease.